Dr. Craig Comiter

Dr. Craig Comiter
Dr. Comiter received his undergraduate degree from Harvard College, and his medical degree from Harvard Medical School. He stayed in Boston for his residency, serving as resident in general surgery at the Brigham and Women’s Hospital, and then completed his urology residency at the Harvard Program in Urology. In 1998, Dr. Comiter served as Clinical Instructor and Fellow in Neurourology and Urodynamics at the University of California in Los Angeles. In 1999, Dr. Comiter joined the faculty at the University of Arizona, as Assistant Professor of Urology. In 2003, he was promoted to Associate Professor, and became Chief of the Section of Urology and Residency Program Director. In 2008, Dr. Comiter moved to Stanford University Medical School as an Associate Professor in the Departments of Urology and Obstetrics & Gynecology, where he started an ABU/ABOG and SUFU accredited fellowship in Female Pelvic Medicine and Reconstructive Surgery. In 2013, Dr. Comiter was promoted to Professor, and the Stanford FPMRS fellowship was approved for ACGME accreditation. He currently serves as Division Chief of Urologic Specialties at Stanford. Dr. Comiter has published more than 100 peer-reviewed articles and 30 book chapters, focusing on BPH, overactive bladder, urinary incontinence, post-prostatectomy incontinence, neuromodulation, urodynamics, and pelvic organ prolapse. He has presented more than 100 peer-reviewed abstracts and given more than 200 invited lectures.
Medical School:

Harvard Medical School


Brigham and Women's Hospital Harvard Medical School, Harvard Program in Urology


University of California Los Angeles


Harvard College, Biology

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only